Amyotrophic Lateral Sclerosis: An Overview

AN OVERVIEW- AMYOTROPHIC LATERAL SCLEROSIS

  • Ravindranath Saudagar Department of Pharmaceutical Chemistry, R.G. Sapkal College of Pharmacy, Anjaneri, Nashik-422213, Maharashtra, India
  • Lajri Garge Department of Pharmaceutical Quality Assurance, R.G. Sapkal College of Pharmacy, Anjaneri, Nashik-422213, Maharashtra, India
DOI https://doi.org/10.22270/jddt.v9i3.2874

Abstract

Amyotrophic Lateral Sclerosis is an adult-onset neurodegenerative disease that causes paralysis. Presently it is incurable and rapidly progressive with a survival of 4-5 years from onset. It is degeneration of upper and lower motor neurons which results in weakness and wasting of muscles in arms, legs, trunk and bulbar region. There are two types sporadic and familial amyotrophic lateral sclerosis. The age of onset of people with familial is widely reported as being about 10 years younger than for those with apparently sporadic amyotrophic lateral sclerosis. Epidemiological studies show a worldwide incidence of 2-3 per year per 100-000 population over age of 15 years. About 10% of individuals have a family history of amyotrophic lateral sclerosis. The cause is unknown. Genes linked to diseases have been identified including one (C9ORF72) that seems to be particulary important. Researchers are studying several causes of ALS like gene mutation, chemical imbalance, disorganized immune response and protein mishandling. Riluzole and Radicava were approved for the treatment by the Food and Drug administration. The diagnosis of ALS is devastating for patient and family members. People with ALS should be delivered with multidisciplinary team. The current hope is that stem cells of neural or extraneural origin might be modified in vitro to neurons that may migrate to the sites of motor neuron loss. The quality of life is important not just the duration of survival.


Keywords: Amyotrophic Lateral Sclerosis, Motor neuron diseases, Sporadic, Familial, Pathogenesis.                                                                                                                                                                                                                 

Downloads

Download data is not yet available.

Author Biographies

Ravindranath Saudagar, Department of Pharmaceutical Chemistry, R.G. Sapkal College of Pharmacy, Anjaneri, Nashik-422213, Maharashtra, India

Department of Pharmaceutical Chemistry, R.G. Sapkal College of Pharmacy, Anjaneri, Nashik-422213, Maharashtra, India

Lajri Garge, Department of Pharmaceutical Quality Assurance, R.G. Sapkal College of Pharmacy, Anjaneri, Nashik-422213, Maharashtra, India

Department of Pharmaceutical Quality Assurance, R.G. Sapkal College of Pharmacy, Anjaneri, Nashik-422213, Maharashtra, India

References

1. Gwinn K, Corriveav RA, Mitsumoto H, Bednarz K, Brown RH, et al., Amyotrophic Lateral Sclerosis: An Emerging Era of Collaborative Gene Discovery, Plos One, 2007; 2(12):1254.
2. Calvo AC, Manzano R, Deise MF, Munoz MJ, Zaragoza P, Osta R, et al., Amyotrophic Lateral Sclerosis: A Focus on Diseases Progression, BioMed Research International, 2014; 1-12.
3. Talbat K, Motor Neuron Diseases, Postgraduation Medical Journal, 2002; 78:513-519.
4. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al., Amyotrophic Lateral Sclerosis. Lancet 2011; 377:942-955.
5. Brown RH, Al-Chalab A, Amyotrophic Lateral Sclerosis, The New England Journal of Medicine, 2017; 377:162-172.
6. Mehta PR, Jones AR, Opie-Martins S, Shatunov A, Lacuangeli A, et al., Younger age of onset in familial amyotrophic lateral sclerosis is a result of pathogenic gene variants, rather than ascertainment bais, Journal of Neurology and Neurosurgery Psychiatry, 2018; O:1-4.
7. Chio A, Traynor BF, Lombardo F, et al., Prevalence of SODI mutations in Italian ALS population, Neurology, 2008; 70:533-537.
8. Morgan S, Orrell RW, Pathogenesis of amyotrophic lateral sclerosis, British Medical Bulletin, 2016; 119:87-89.
9. Lattante S, Rouleau GA, Kabashi E, TARDBP and FUS mutations associated with Amyotrophic lateral Sclerosis: Summary, Human Mutations, 2013; 34:812-826.
10. Paez-Colasante X, Figueroa-Romero C, Sakowski SA, Goutman SA, Feldman EL, Amyotrophic Lateral Sclerosis: mechanisms and therapeutics in the epigenomic era, Nature Reviews Neurology, 2015; 57:1-14.
11. Ricci C, Marzocchi C, Battistini S, Micro RNAs as Biomarkers in Amyotrophic Lateral Sclerosis, Cells, 2018; 7:211-219.
12. Orrell RW, Motor Neuron Diseases: systematic reviews of treatment for ALS and SMS, British Medical Bulletin, 2010; 93:145-159.
13. Mclntosh J, Murrell M, All about amyotrophic lateral sclerosis, Medical News Today, 2019; 1-8.
Statistics
45 Views | 88 Downloads
How to Cite
Saudagar, R., & Garge, L. (2019). Amyotrophic Lateral Sclerosis: An Overview. Journal of Drug Delivery and Therapeutics, 9(3), 613-616. https://doi.org/10.22270/jddt.v9i3.2874
Issue
Vol 9 No 3 (2019): Volume 9, Issue 3, May-June 2019
Section
Review
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with this journal agree to the following terms:

 

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.

 

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.

 

  1. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

Â